
Packaging Compliance Labs Completes Acquisition of Quest Engineering Solutions, Expands Testing Capabilities and East Coast Presence

SUN Behavioral Health Acquires Seaside’s Community Agencies, Expanding Access to Community-Based Mental Health Services Across the Southeast

Centauri Health Solutions Acquires MedAllies, Broadens Health Data Network to Support Mission Critical Use Cases
British Patient Capital announces £25m commitment to SV Health Investors’ Dementia Discovery Fund 2

Ria Health Raises Growth Capital to Accelerate Access to Patient-Driven AUD Treatment

2024 SV Therapeutics Impact & ESG Report
Read More

Alpheus Medical Announces Positive Phase 1/2 Trial Results for the Treatment of Recurrent High-Grade Gliomas

Data Presented at the American College of Chest Physicians Correlates Airway Remodeling with Positive Clinical Outcomes Utilizing the RejuvenAir® System

SpectraWAVE Announces $50M Series B Financing to Drive Commercial Expansion and Product Additions to the HyperVue™ Imaging System

Pulse Biosciences, Inc. Appoints Paul LaViolette to Its Board of Directors - Paul LaViolette to serve as Co-Chairman alongside Robert W. Duggan, adding 40 years of medical technology development, operating and leadership expertise

Spineology® Announces $25 Million Equity Financing – Funding to aid in acceleration of commercial growth, clinical education programs, and product development enhancements for highly-differentiated OptiMesh® implant portfolio –

Edwards Lifesciences Expands Structural Heart Portfolio With Acquisitions of JenaValve and Endotronix

Endotronix Receives FDA Premarket Approval of the Cordella™ PA Sensor System for the Treatment of Heart Failure

Merck signs $3bn deal for Kate Bingham-backed eye disease biotech
Read More

SV Health Investors-created EyeBio to be acquired by MSD for up to $3 billion

Nanopath Receives $4 Million in Grants from National Institutes of Health and National Science Foundation

QurAlis to Present Data That Show its Splice-Switching ASOs Restore UNC13A Function in ALS and Frontotemporal Dementia
SV investment has resulted in the approval of 24 novel therapeutics

SV Health Investors bolsters senior biotech team - appoints Nikola Trbovic as Managing Partner and hires Jamil Beg as Partner

Hightop Health adds industry veteran to Board of Directors - Seasoned CEO and McLean Hospital Board Chair joins Hightop’s executive leadership

Merck to Acquire Caraway Therapeutics, Inc.

EyeBio Announces Expansion of Series A to $130 Million, Advances Development of Restoret for Retinal Diseases

SV Health Investors partners with HIT Executives Dave Dyell and Marc Hirshfield to Lead Recapitalization of Innovative Consulting Group
SV News
- 12 April 2024Portfolio NewsPrilenia to Present Latest Research from its Pridopidine Programs for Huntington Disease and ALS at AAN 2024
- 10 April 2024Portfolio NewsSitryx nominates SYX-5219 a novel, oral and targeted PKM2 activator for clinical development in atopic dermatitis
- 8 April 2024Portfolio NewsPositive Results for Patients with Non-obstructive Hypertrophic Cardiomyopathy Treated with Ninerafaxstat in the Phase 2 IMPROVE-HCM Trial Presented During a Late-Breaking Clinical Trial Session at ACC.24
- 7 April 2024Portfolio NewsRibometrix Presents First c-MYC Data Validating RNA-Targeting Platform and Demonstrates Synergistic Potential of eIF4E Program at AACR 2024
- 28 March 2024Portfolio NewsGilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 Program
- 26 March 2024SV NewsSV Biotech launches its inaugural ESG and Impact Report
- 21 March 2024SV NewsUK dementia adviser [Ruth McKernan] wants half a million volunteers for clinical trials
- 12 March 2024Portfolio NewsPrilenia Plans to Submit Marketing Authorization Application (MAA) in the EU for Pridopidine in Huntington’s Disease
- 11 March 2024Portfolio NewsRibometrix to Present New Preclinical Data From RNA-Modulating Small Molecule Programs Targeting eIF4E and c-MYC at the 2024 AACR Annual Meeting
- 8 March 2024SV NewsOn International Women's Day SV Venture Partner Ruth McKernan reflects on some achievements of SV biotech portfolio companies
- 13 February 2024Portfolio NewsBioAge raises $170M as obesity spotlight shifts to oral options, muscle preservers
- 13 February 2024Portfolio NewsEyeBio targets registrational trial after early success of Wnt agonist in retinal diseases